EUCTR2006-001456-12-DK进行中（未招募）不适用
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of informed consent
- •2.Female or male aged 18 years and over
- •3.Histological or cytological confirmation of unresectable AJCC stage 3 or 4 malignant melanoma
- •4.At least one measurable site of disease (using CT/MRI) as defined by RECIST
- •5.WHO performance status 0-2 (patients performance status 2 must have been stable with no deterioration over the previous 2 weeks)
- •6.Willing to provide a fresh, or archival tumour biopsy for determination of BRAF and NRAS mutational status
- •7.Evidence of post-menopausal status, or negative urinary pregnancy test for female pre-menopausal patients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Laboratory values as listed below:
- •-Absolute Neutrophil Count (ANC) <1500 per cubic mm
- •-Platelets <100,000 per cubic mm
- •-Haemoglobin (Hgb) =9.0 g/dL
- •-Serum bilirubin =1.5 times the upper limit of normal (ULN)
- •-Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) =2.5 times ULN
- •-Serum creatinine =1.5 mg/dL
- •2.Calculated serum creatinine clearance =30 mL/min (using Cockcroft-Gault formula)
- •3.Prior cancer treatment as follows:
- •-Any systemic chemotherapy for AJCC stage 3 or 4 melanoma
- •-Prior radiotherapy within the 5 years before starting study treatment excluding palliative radiotherapy at focal sites. Radiotherapy to treat primary uveal melanoma is permitted
- •-Prior chemotherapy within the 5 years prior to starting study treatment
- •Prior treatment with immunomodulatory agent, vaccine therapy or gene therapy alone is acceptable (combination biochemotherapy is not permitted)
- •4.Have received an investigational drug within the 30 days prior to entry or who have not recovered from side effects of an investigational study drug
- •5.Recent major surgery within 4 weeks prior to informed consent
- •6.Brain metastases or spinal cord compression unless treated and stable (for at least 3 months) off steroids
- •7.Patients with a history of another primary malignancy within 5 years prior to starting study treatment except for adequately treated basal or squamous cell carcinoma or carcinoma of the cervix in situ
- •8.Any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, severe renal impairment, uncontrolled diabetes, acute uncontrolled infection) or current unstable or uncompensated respiratory or cardiac conditions or peripheral vascular disease including diabetic vasculopathy
- •9.Evidence of active infection or active bleeding diatheses
- •10.Documented cases of human immunodeficiency virus (HIV) or hepatitis B or C
- •11.Refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption
- •12.Mean QTc interval >450 ms
- •13.Presence of factors that may increase the risk of QT prolongation or arrhythmic events (eg, heart failure, hypokalaemia, family history, or long QT syndrome)
- •14.Receiving concomitant medication that may cause QT prolongation
- •15.Known hypersensitivity to AZD6244, Captisol®, or temozolomide
- •16.Female patients who are breast feeding, or patients of reproductive potential not employing an effective method of birth control
- •17.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- •18.Previous enrolment or randomisation of treatment in the present study
- •19. Patients diagnosed with uveal melanoma, following closure of recruitment to such patients. (Recruitment will be closed to patients with uveal melanoma when AstraZeneca is notified that 20 patients with this diagnosis have been randomised)
研究者
相似试验
进行中（未招募）
1 期
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant MelanomaEUCTR2006-001456-12-GBAstraZeneca AB200
进行中（未招募）
不适用
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanomanresectable AJCC Stage 3 or 4 Malignant MelanomaEUCTR2006-001456-12-ATAstraZeneca AB182
进行中（未招募）
1 期
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanomanresectable AJCC Stage 3 or 4 Malignant MelanomaMedDRA version: 8.1Level: PTClassification code 10025650Term: Malignant melanomaEUCTR2006-001456-12-FRAstraZeneca AB200
进行中（未招募）
1 期
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1)Human immunodeficiency virus infectionEUCTR2017-000050-18-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.32
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003616-13-BETurning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)630